{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:07:43Z","timestamp":1773392863831,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12094-019-02252-2","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T19:02:49Z","timestamp":1577127769000},"page":"1414-1417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Utility of PET\/CT in patients with stage I\u2013III melanoma"],"prefix":"10.1007","volume":"22","author":[{"given":"J. A.","family":"Avil\u00e9s Izquierdo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Molina L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sobrini Morillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2476-668X","authenticated-orcid":false,"given":"I.","family":"M\u00e1rquez Rodas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mercader Cidoncha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"2252_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Cutaneous melanoma version 1. 2019. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf. Accessed 1 Nov 2018."},{"key":"2252_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.rx.2016.03.007","volume":"58","author":"JL Vercher-Conejero","year":"2016","unstructured":"Vercher-Conejero JL, G\u00e1mez Cenzano C. 18F-FDG positron emission tomography in oncology: main indications. Radiolog\u00eda. 2016;58:303\u201319.","journal-title":"Radiolog\u00eda"},{"key":"2252_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","volume":"42","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Larribere L, Pan L, Hberkorn U, Dimitrakopoulou-Strauss A, Hassel J. Predictive value of early 18F-FDG PET\/TC studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015;42:386\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2252_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cpet.2014.12.006","volume":"10","author":"EM Rohren","year":"2015","unstructured":"Rohren EM. PET\/computed tomography and patient outcomes in melanoma. PET Clin. 2015;10:243\u201354.","journal-title":"PET Clin."},{"key":"2252_CR5","first-page":"259","volume":"205","author":"P Perng","year":"2015","unstructured":"Perng P, Marcus C, Subramaniam R. 18F-FDG PET\/TC and melanoma: staging, immune modulation and mutation-targeted therapy assessment, and prognosis. Nucl Med Mol Imaging (USA). 2015;205:259\u201370.","journal-title":"Nucl Med Mol Imaging (USA)"},{"key":"2252_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamaophthalmol.2013.564","volume":"131","author":"J Wen","year":"2013","unstructured":"Wen J, Sai V, Straatsma B, McCannel T. Radiation-related cancer risk associated with surveillance imaging for metastasis from choroidal melanoma. JAMA Ophthalmol. 2013;131:56\u201361.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"2252_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1524-4725.2010.01479.x","volume":"36","author":"J Klode","year":"2010","unstructured":"Klode J, Dissemond J, Grabbe S, Hillen U, Poeppel T, Boeing C. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II. Dermatol Surg. 2010;36(4):439\u201345.","journal-title":"Dermatol Surg"},{"key":"2252_CR8","first-page":"96","volume":"35","author":"A Ortega-Candil","year":"2016","unstructured":"Ortega-Candil A, Rodr\u00edguez-Rey C, Cano-Carrizal R, Cala-Zuluaga E, Gonz\u00e1lez JL, Jin\u00e9nez A, et al. Breslow thickness and (18)F-FDG PET-CT result in initial staging of cutaneous melanoma: can a cut-off point be established? Rev Esp Med Nucl Imagen Mol. 2016;35:96\u2013101.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"2252_CR9","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1111\/jdv.13718","volume":"31","author":"MA Chessa","year":"2017","unstructured":"Chessa MA, Dika E, Patrizi A, Fanti PA, Piraccini BM, Veronesi G, et al. Sentinel lymph node biopsy versus PET-TC in AJCC stages I and II of melanoma. J Eur Acad Dermatol Venereol. 2017;31:e54\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2252_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00259-015-3187-2","volume":"43","author":"SC Sch\u00fcle","year":"2016","unstructured":"Sch\u00fcle SC, Eigentler TK, Garbe C, La foug\u00e8re C, Nikolaou K, Pfannenberg C. Influence of 18F-FDG PET\/TC on therapy management in patients with stage III\/IV malignant melanoma. Eur J Nucl Med Mol Imaging. 2016;43:482\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2252_CR11","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1111\/jdv.13084","volume":"29","author":"E Gell\u00e9n","year":"2015","unstructured":"Gell\u00e9n E, S\u00e1ntha O, Janka E, Juh\u00e1sz I, P\u00e9ter Z, Erdei I, et al. Diagnostic accuracy of 18F-FDG-PET\/TC in early and late stages of high-risk cutaneous malignant melanoma. J Eur Acad Dermatol Venereol. 2015;29:1938\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2252_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2015.3664","volume":"2","author":"B Scheier","year":"2016","unstructured":"Scheier B, Lao C, Kidwell K, Redman B. Use of preoperative PET\/TC staging in sentinel lymph node-positive melanoma. JAMA Oncol. 2016;2:136\u20137.","journal-title":"JAMA Oncol"},{"issue":"17","key":"2252_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1186\/s12885-017-3626-5","volume":"2017","author":"B van der Hiel","year":"2017","unstructured":"van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM, REPOSIT study group. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. BMC Cancer. 2017;2017(17):649.","journal-title":"BMC Cancer"},{"key":"2252_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/pcmr.12503","volume":"29","author":"BY Kong","year":"2016","unstructured":"Kong BY, Menzies AM, Saunders CA, Liniker E, Ramanujam S, Guminski A, Kefford RF, Long GV, Carlino MS. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res. 2016;29:572\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"key":"2252_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.rcl.2013.06.004","volume":"51","author":"A Bourgeois","year":"2013","unstructured":"Bourgeois A, Chang T, Fish L, Bradley Y. Positron emission tomography\/computed tomography in melanoma. Radiol Clin N Am. 2013;51:865\u201379.","journal-title":"Radiol Clin N Am"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02252-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02252-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02252-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:31:14Z","timestamp":1608597074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02252-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2252"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02252-2","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]},"assertion":[{"value":"29 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"IMR declares the following conflict of interest: advisory role from BMS, MSD, Novartis, Roche, Pierre Fabre, Incyte, Amgen, Merck-Serono, Sanofi, Regeneron and Bioncotech. The rest of the authors declare no conflict of interest with the specific topic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients, prior to the imaging study, were asked to sign a consent form. The study fulfills the declaration of Helsinki ethical standards for research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Our research involved human participants who had obtained informed consents. The study fulfills the declaration of Helsinki ethical standards for research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}